Cover Image

Association of airway inflammation and smoking status with IL-33 level in sputum of patients with asthma or COPD

Asthma and COPD are heterogeneous inflammatory airway conditions. Interleukin (IL)-33 is an epithelial pleiotropic cytokine that regulates type 1 and type 2 immune responses [1]. Clinical trials have shown promising efficacy of monoclonal antibodies targeting IL-33 and its ST2 receptor in asthma and...

Full description

Saved in:
Bibliographic Details
Main Authors: Abdo, Mustafa (Author) , Pedersen, Frauke (Author) , Kirsten, Anne-Marie (Author) , Trinkmann, Frederik (Author) , Groth, Espen E. (Author) , Bahmer, Thomas (Author) , Watz, Henrik (Author) , Rabe, Klaus F. (Author)
Format: Article (Journal) Editorial
Language:English
Published: 2024
In: The European respiratory journal
Year: 2024, Volume: 64, Issue: 3, Pages: 1-5
ISSN:1399-3003
DOI:10.1183/13993003.00347-2024
Online Access:Verlag, kostenfrei, Volltext: https://doi.org/10.1183/13993003.00347-2024
Verlag, kostenfrei, Volltext: https://publications.ersnet.org/content/erj/64/3/2400347
Get full text
Author Notes:Mustafa Abdo, Frauke Pedersen, Anne-Marie Kirsten, Frederik Trinkmann, Espen E. Groth, Thomas Bahmer, Henrik Watz, Klaus F. Rabe
Description
Summary:Asthma and COPD are heterogeneous inflammatory airway conditions. Interleukin (IL)-33 is an epithelial pleiotropic cytokine that regulates type 1 and type 2 immune responses [1]. Clinical trials have shown promising efficacy of monoclonal antibodies targeting IL-33 and its ST2 receptor in asthma and COPD [2-4]. So far, little is known about the characterisation of airway inflammation associated with increased IL-33 levels in patients with asthma or COPD. Moreover, previous studies have reported a potential impact of smoking status on IL-33 protein levels [5]. Therefore, we investigated the association of smoking status and airway inflammatory phenotypes with IL-33 levels in patients with asthma or COPD. Such clinical characterisation could provide new insights for selecting patients who might benefit from anti-IL-33 therapy.
Item Description:Gesehen am 04.08.2025
Physical Description:Online Resource
ISSN:1399-3003
DOI:10.1183/13993003.00347-2024

Similar Items